Debt-to-equity of Kezar Life Sciences, Inc. from 31 Mar 2019 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Kezar Life Sciences, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2019 to 30 Sep 2025.
  • Kezar Life Sciences, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 21%, a 8.5% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Kezar Life Sciences, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 21% +2% +8.5% 30 Sep 2025
Q2 2025 22% +4% +25% 30 Jun 2025
Q1 2025 22% +6% +36% 31 Mar 2025
Q4 2024 21% +6% +40% 31 Dec 2024
Q3 2024 19% +6% +48% 30 Sep 2024
Q2 2024 17% +6% +59% 30 Jun 2024
Q1 2024 16% +7% +70% 31 Mar 2024
Q4 2023 15% +6% +74% 31 Dec 2023
Q3 2023 13% +5% +59% 30 Sep 2023
Q2 2023 11% +2% +29% 30 Jun 2023
Q1 2023 9% 0% +2.6% 31 Mar 2023
Q4 2022 8% -1% -8.6% 31 Dec 2022
Q3 2022 8% 0% -1.1% 30 Sep 2022
Q2 2022 9% +1% +11% 30 Jun 2022
Q1 2022 9% +2% +24% 31 Mar 2022
Q4 2021 9% +2% +20% 31 Dec 2021
Q3 2021 8% 0% -5.4% 30 Sep 2021
Q2 2021 8% -2% -23% 30 Jun 2021
Q1 2021 7% -4% -38% 31 Mar 2021
Q4 2020 8% -5% -37% 31 Dec 2020
Q3 2020 9% -1% -11% 30 Sep 2020
Q2 2020 10% +2% +25% 30 Jun 2020
Q1 2020 12% +5% +80% 31 Mar 2020
Q4 2019 12% 31 Dec 2019
Q3 2019 10% 30 Sep 2019
Q2 2019 8% 30 Jun 2019
Q1 2019 7% 31 Mar 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.